Shopping Cart 0
Cart Subtotal
USD 0

Theravance Biopharma Inc (TBPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Theravance Biopharma Inc (Theravance Biopharma) is a diversified biopharmaceutical company. Its flagship product, Vibativ (telavancin) is a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to Staphylococcus aureus and other Gram-positive bacteria, including methicillin-resistant (MRSA) strains. Its major pipeline programs targeted towards the treatment of chronic obstructive pulmonary disease (COPD); asthma; neurogenic orthostatic hypotension (nOH); opioid-induced constipation (OIC); hepatitis C virus; gastrointestinal motility disorders; ulcerative colitis; heart failure; chronic kidney disease (CKD); Crohn's disease; gastroparesis; concurrent bacteremia; rheumatoid arthritis; and myelofibrosis and blood pressure. The company has subsidiaries in the US, Ireland and the UK. Theravance is headquartered in George Town, Cayman Islands, the UK.

Theravance Biopharma Inc (TBPH)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Theravance Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Janssen Biotech Enters into Co-Development Agreement with Theravance Biopharma Ireland 11

Theravance Biopharma Enters into Development and Commercialization Agreement with Mylan 12

Licensing Agreements 13

Takeda Pharma Enters into Licensing Agreement with Theravance Biopharma for TD-8954 13

Trek Therapeutics Enters into Licensing Agreement with Theravance Biopharma 14

Theravance Biopharma Enters into Co-Development Agreement with SciClone Pharma 15

Equity Offering 16

Theravance Biopharma Raises USD100 Million in Public Offering of Shares 16

Theravance Biopharma Raises USD115 Million in Public Offering of Shares 18

Theravance Biopharma Raises USD23 Million in Private Placement of Shares 20

Theravance Biopharma Raises USD55 Million in Private Placement of Shares 21

Debt Offering 23

Theravance Biopharma Raises USD230 Million in Public Offering of 3.25% Notes Due 2023 23

Asset Transactions 25

Cumberland Pharma to Acquire Vibative from Theravance Biopharma 25

Theravance Biopharma Inc-Key Competitors 26

Theravance Biopharma Inc-Key Employees 27

Theravance Biopharma Inc-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 29

Financial Announcements 29

Nov 06, 2018: Theravance Biopharma reports third quarter 2018 financial results and provides business update 29

Aug 01, 2018: Theravance Biopharma reports second quarter 2018 financial results and provides business update 31

May 08, 2018: Theravance Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update 33

Feb 27, 2018: Theravance Biopharma Announces Fourth Quarter and Full Year 2017 Financial Results 35

Nov 07, 2017: Theravance Biopharma Reports Third Quarter 2017 Financial Results and Provides Business Update 37

Aug 08, 2017: Theravance Biopharma Reports Second Quarter 2017 Financial Results and Provides Business Update 39

May 09, 2017: Theravance Biopharma Reports First Quarter 2017 Financial Results and Provides Business Update 41

Feb 27, 2017: Theravance Biopharma Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update 43

Corporate Communications 45

Jul 31, 2017: Theravance Biopharma Appoints Shehnaaz Suliman, MD, as Senior Vice President of Corporate Development and Strategy 45

Product News 46

05/17/2017: Theravance Biopharma and Mylan to Present Additional Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS 46

01/29/2018: Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease 47

01/23/2017: Theravance Biopharma Reports New Data from Ongoing TOUR Observational Patient Registry in Oral Presentation at SCCM Critical Care Congress 48

01/17/2017: Theravance Biopharma to Present New Data from Ongoing TOUR Observational Patient Registry at SCCM Critical Care Congress 50

Product Approvals 51

Nov 13, 2017: Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease 51

Clinical Trials 52

Nov 01, 2017: Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting 52

Oct 24, 2017: Theravance Biopharma to Present New Data on Revefenacin (TD-4208) at 2017 CHEST Annual Meeting 54

Jul 19, 2017: Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD) 55

May 23, 2017: Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS 56

Feb 17, 2017: Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization 58

Feb 13, 2017: Theravance Biopharma to Present Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization 59

Appendix 60

Methodology 60

About GlobalData 60

Contact Us 60

Disclaimer 60


List Of Figure

List of Figures

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Theravance Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Theravance Biopharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Janssen Biotech Enters into Co-Development Agreement with Theravance Biopharma Ireland 11

Theravance Biopharma Enters into Development and Commercialization Agreement with Mylan 12

Takeda Pharma Enters into Licensing Agreement with Theravance Biopharma for TD-8954 13

Trek Therapeutics Enters into Licensing Agreement with Theravance Biopharma 14

Theravance Biopharma Enters into Co-Development Agreement with SciClone Pharma 15

Theravance Biopharma Raises USD100 Million in Public Offering of Shares 16

Theravance Biopharma Raises USD115 Million in Public Offering of Shares 18

Theravance Biopharma Raises USD23 Million in Private Placement of Shares 20

Theravance Biopharma Raises USD55 Million in Private Placement of Shares 21

Theravance Biopharma Raises USD230 Million in Public Offering of 3.25% Notes Due 2023 23

Cumberland Pharma to Acquire Vibative from Theravance Biopharma 25

Theravance Biopharma Inc, Key Competitors 26

Theravance Biopharma Inc, Key Employees 27

Theravance Biopharma Inc, Subsidiaries 28

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Theravance Biopharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

Theravance Biopharma Inc (Theravance Biopharma) is a diversified biopharmaceutical company. Its flagship product, Vibativ (telavancin) is a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to Staphylococcus aureus and other Gram-positive bacteria, including methicillin-resistant (MRSA) strains. Its major pipeline programs targeted towards the treatment of chronic obstructive pulmonary disease (COPD); asthma; neurogenic orthostatic hypotension (nOH); opioid-induced constipation (OIC); hepatitis C virus; gastrointestinal motility disorders; ulcerative colitis; heart failure; chronic kidney disease (CKD); Crohn's disease; gastroparesis; concurrent bacteremia; rheumatoid arthritis; and myelofibrosis and blood pressure. The company has subsidiaries in the US, Ireland and the UK. Theravance is headquartered in George Town, Cayman Islands, the UK.

Theravance Biopharma Inc (TBPH)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Theravance Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Janssen Biotech Enters into Co-Development Agreement with Theravance Biopharma Ireland 11

Theravance Biopharma Enters into Development and Commercialization Agreement with Mylan 12

Licensing Agreements 13

Takeda Pharma Enters into Licensing Agreement with Theravance Biopharma for TD-8954 13

Trek Therapeutics Enters into Licensing Agreement with Theravance Biopharma 14

Theravance Biopharma Enters into Co-Development Agreement with SciClone Pharma 15

Equity Offering 16

Theravance Biopharma Raises USD100 Million in Public Offering of Shares 16

Theravance Biopharma Raises USD115 Million in Public Offering of Shares 18

Theravance Biopharma Raises USD23 Million in Private Placement of Shares 20

Theravance Biopharma Raises USD55 Million in Private Placement of Shares 21

Debt Offering 23

Theravance Biopharma Raises USD230 Million in Public Offering of 3.25% Notes Due 2023 23

Asset Transactions 25

Cumberland Pharma to Acquire Vibative from Theravance Biopharma 25

Theravance Biopharma Inc-Key Competitors 26

Theravance Biopharma Inc-Key Employees 27

Theravance Biopharma Inc-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 29

Financial Announcements 29

Nov 06, 2018: Theravance Biopharma reports third quarter 2018 financial results and provides business update 29

Aug 01, 2018: Theravance Biopharma reports second quarter 2018 financial results and provides business update 31

May 08, 2018: Theravance Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update 33

Feb 27, 2018: Theravance Biopharma Announces Fourth Quarter and Full Year 2017 Financial Results 35

Nov 07, 2017: Theravance Biopharma Reports Third Quarter 2017 Financial Results and Provides Business Update 37

Aug 08, 2017: Theravance Biopharma Reports Second Quarter 2017 Financial Results and Provides Business Update 39

May 09, 2017: Theravance Biopharma Reports First Quarter 2017 Financial Results and Provides Business Update 41

Feb 27, 2017: Theravance Biopharma Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update 43

Corporate Communications 45

Jul 31, 2017: Theravance Biopharma Appoints Shehnaaz Suliman, MD, as Senior Vice President of Corporate Development and Strategy 45

Product News 46

05/17/2017: Theravance Biopharma and Mylan to Present Additional Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS 46

01/29/2018: Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease 47

01/23/2017: Theravance Biopharma Reports New Data from Ongoing TOUR Observational Patient Registry in Oral Presentation at SCCM Critical Care Congress 48

01/17/2017: Theravance Biopharma to Present New Data from Ongoing TOUR Observational Patient Registry at SCCM Critical Care Congress 50

Product Approvals 51

Nov 13, 2017: Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease 51

Clinical Trials 52

Nov 01, 2017: Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting 52

Oct 24, 2017: Theravance Biopharma to Present New Data on Revefenacin (TD-4208) at 2017 CHEST Annual Meeting 54

Jul 19, 2017: Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD) 55

May 23, 2017: Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS 56

Feb 17, 2017: Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization 58

Feb 13, 2017: Theravance Biopharma to Present Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization 59

Appendix 60

Methodology 60

About GlobalData 60

Contact Us 60

Disclaimer 60


List Of Figure

List of Figures

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Theravance Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Theravance Biopharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Janssen Biotech Enters into Co-Development Agreement with Theravance Biopharma Ireland 11

Theravance Biopharma Enters into Development and Commercialization Agreement with Mylan 12

Takeda Pharma Enters into Licensing Agreement with Theravance Biopharma for TD-8954 13

Trek Therapeutics Enters into Licensing Agreement with Theravance Biopharma 14

Theravance Biopharma Enters into Co-Development Agreement with SciClone Pharma 15

Theravance Biopharma Raises USD100 Million in Public Offering of Shares 16

Theravance Biopharma Raises USD115 Million in Public Offering of Shares 18

Theravance Biopharma Raises USD23 Million in Private Placement of Shares 20

Theravance Biopharma Raises USD55 Million in Private Placement of Shares 21

Theravance Biopharma Raises USD230 Million in Public Offering of 3.25% Notes Due 2023 23

Cumberland Pharma to Acquire Vibative from Theravance Biopharma 25

Theravance Biopharma Inc, Key Competitors 26

Theravance Biopharma Inc, Key Employees 27

Theravance Biopharma Inc, Subsidiaries 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Theravance Biopharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.